$REG

Whole Foods, Shake Shack coming to St. Johns County’s fastest-growing community

Regency Centers said it is developing the grocery-anchored open-air shopping center “The Berkeley at Durbin Park” in St. Johns County, Fla., near UF Health Durbin Park. The company plans groundbreaking in Q4 2026 and lists Whole Foods as the anchor, with TJ Maxx, Firebirds Wood Fired Grill, and Shake Shack as tenants. Regency also cites a separate 250,000-sq-ft project, The Village at Seven Pines.

Original reporting
Published Jul 6, 2026, 6:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 7:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Whole Foods, Shake Shack coming to St. Johns County’s fastest-growing community — source image
Decision brief

The 30-second read

$REGBullishLow
01

Why it matters

The tenant lineup (Whole Foods, TJ Maxx, Firebirds, Shake Shack) and planned Q4 2026 groundbreaking provide incremental pipeline detail, but the lack of financial terms limits near-term trading impact.

02

Market read

A regional development/pipeline update for Regency Centers with named tenants, but no disclosed financials or lease terms.

03

What to watch

Traders may want to verify whether Whole Foods and Shake Shack leases are signed/secured and whether any anchor tenant changes could affect project timing or returns.

Relevance 4/10Novelty 4/10Timing: groundbreaking planned for Q4 2026 (pipeline update)

Background

Regency Centers is a REIT focused on retail properties; this article describes a new grocery-anchored, open-air shopping center in St. Johns County, Florida.

Company-level read

Ticker impact

$REGBullishMedium confidence
Context

Regency Centers is developing The Berkeley at Durbin Park, with Whole Foods and Shake Shack as tenants, and plans Q4 2026 groundbreaking.

Expected impact

Likely modest, if any, near-term impact; more relevant for longer-dated development/pipeline sentiment.

Evidence & confidence

The article discloses a new grocery-anchored center and tenant roster, but provides no capex, lease terms, or financial guidance that would drive a large immediate repricing.

Market effects

Supports the broader theme of grocery-anchored retail development and tenant demand in suburban growth corridors.

Highlights continued investment in the Jacksonville metro (Durbin Park area), which can marginally improve local retail leasing expectations.

Limited; primarily a regional real-estate development update.

Counterpoint

Without disclosed lease economics or project cost, the news may be more marketing than a material earnings driver.

Key entities

  • Regency Centers

    Developer of The Berkeley at Durbin Park, with a stated Q4 2026 groundbreaking plan and named tenants.

  • Whole Foods Market

    Announced as the grocery anchor for the development.

  • Shake Shack

    Announced as part of the tenant lineup for the development.

Related articles

$EVGOMed

EVgo, Regency expand partnership with 400 new EV charging stalls

EVgo and Regency Centers are adding 400 fast-charging stalls at U.S. shopping centers, expanding their 2020 partnership. The new stations will increase Regency's EV charging footprint by over 20%, with locations in major markets. EVgo's chargers can fully charge a vehicle in 15 minutes. The companies aim to meet EV driver demand and support sustainability goals.

$JNJMed

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

Johnson & Johnson (JNJ) reported that its RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) combination showed a 77% overall response rate in first-line treatment of advanced head and neck cancer. The study, presented at ESMO Congress 2026, demonstrated deep and durable responses, with 65% ongoing at clinical cutoff. The results support the ongoing Phase 3 OrigAMI-5 study and highlight the role of dual-targeting EGFR and MET, key drivers of tumor growth and resistance in 80-90% of HNSCC.

$AVBPMedAI 8/10

ArriVent reports phase 1 data for cancer drug ARR-217

ArriVent BioPharma (AVBP) reported initial Phase 1 results for ARR-217, showing a 44.8% objective response rate at 6 mg/kg dose in pre-treated colorectal cancer patients. The study included 123 patients with gastrointestinal malignancies. ARR-217 is being developed with Lepu Biopharma. Phase 1b dose optimization is underway, with further data expected in 2027.

$AVBPMedAI 8/10

At one dose, an experimental cancer drug had a 44.8% response rate after earlier colorectal cancer treatments.

ArriVent BioPharma (AVBP) reported Phase 1 results for ARR-217, showing a 44.8% response rate in colorectal cancer patients at a 6mg/kg dose. The drug was generally well-tolerated. ArriVent plans a Phase 1b dose optimization study, with data expected in 2027. ARR-217 is a cadherin-17-targeting antibody-drug conjugate developed with Lepu Biopharma.